P-PSMA-101 CAR-T cells for Metastatic Castration Resistant Prostate Cancer
Study Summary
This trial is testing a new treatment for men with metastatic prostate cancer that has not responded to other treatments. The treatment involves taking the patient's own immune cells, engineering them to better target the cancer, and infusing them back into the patient.
- Metastatic Castration Resistant Prostate Cancer
- Prostate Disease
- Prostate Cancer
- Tumors
- Salivary Gland Cancer
- Salivary Duct Cancer
- Urogenital Neoplasms
- Male Genital Neoplasms
- Acinic Cell Carcinoma
- Adenoid Cystic Carcinoma
- Castration-resistant Prostate Cancer
- Mucoepidermoid Carcinoma
- Cancer
- Salivary Gland Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 0 Secondary · Reporting Duration: Baseline through 15 years
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
P-PSMA-101 CAR-T cells (Single Dose - Part 1a)
1 of 4
P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)
1 of 4
P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)
1 of 4
P-PSMA-101 CAR-T cells (Single Dose - Part 1c)
1 of 4
Experimental Treatment
60 Total Participants · 4 Treatment Groups
Primary Treatment: P-PSMA-101 CAR-T cells · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How extensive is the geographical reach of this trial?
"The Dana-Farber Cancer Institute in Boston, City of Hope Comprehensive Cancer Center in Duarte and University of California San Francisco in San Francisco are a few clinical trial sites participating. Additionally, there are 10 other locations running the study." - Anonymous Online Contributor
Is the research team seeking out participants for this trial?
"This clinical trial has ceased recruitment of new patients; the original posting was made on February 28th 2020, and the last update was November 15th 2022. However, there are currently 5896 ongoing studies regarding prostatic diseases as well as 16 distinct trials searching for participants to evaluate P-PSMA-101 CAR-T cells treatments." - Anonymous Online Contributor
Has the effectiveness of P-PSMA-101 CAR-T cells been explored in prior research studies?
"As of now, there are 16 clinical investigations underway surrounding P-PSMA-101 CAR-T cells with none in their terminal phase. Most experiments relating to this subject matter are taking place in Nashville, Tennessee while 94 other sites worldwide have begun trials focusing on the same topic." - Anonymous Online Contributor
Has the FDA granted approval for P-PSMA-101 CAR-T cell treatments?
"With limited clinical data indicating efficacy and safety, the P-PSMA-101 CAR-T cell scored a 1 on our team's rating system." - Anonymous Online Contributor
How many participants are involved with this experiment?
"Unfortunately, the recruitment period for this clinical trial has closed. It was first posted on February 28th 2020 and last modified on November 15th 2022. However, there are currently 5896 studies recruiting participants with prostatic diseases as well as 16 trials looking for patients to receive P-PSMA-101 CAR-T cells." - Anonymous Online Contributor